TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of Participants Discontinuing Study Therapy Due to an AE
Endpoint domain: Adverse events/effects
Primary endpoint: Toxicities frequency
Endpoint domain: Adverse events/effects
Primary endpoint: Days of Primary Substance Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Substance-related problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Times engaging in risky behaviors
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Simple Reaction Time With the Dominant Hand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Simple Reaction Time With the Dominant Foot
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Choice Reaction Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response Time Involving the Dominant Hand (Fitts Law Test)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response Time Involving Whole Body Movement (T-wall)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Schwartz Outcome Scale (SOS-10)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Surgery conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Severity of GD irritation in the stomach and duodenum as measured by the Lanza score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Total number of GD erosions overall
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: % Change in Body Mass Index (BMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in plasma cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Safety evaluated by adverse event(s)
Endpoint domain: Adverse events/effects
Primary endpoint: Diagnostic accuracy of dry electrode cap EEG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful passages of biliary (pancreatic) stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Pain and discomfort during and after procedures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of deaths of individuals with viral hemorrhagic fever
Endpoint domain: Mortality/survival
Primary endpoint: Change in stool quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change from baseline urinary concentrations of total p-cresol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Childhood Autism Rating Scale (CARS)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Repetitive Behavior Scale-Revised (RBS-R)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Conners' Parent Rating Scale - Revised (CPRS-R)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Social Responsiveness Scale (SRS)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Area under the curve of sensor glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Quality of Sleep (Subjective)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Area Under the Concentration-time Curve of the Empagliflozin in Plasma (AUC0-tz)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area Under the Concentration-time Curve of the Metformin in Plasma (AUC0-tz)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum Measured Concentration of the Empagliflozin in Plasma (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum Measured Concentration of the Metformin in Plasma (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in intestinal microbiome composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of intubation
Endpoint domain: Mortality/survival
Primary endpoint: disease event-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Fat fraction of GI content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Self reported pain score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Exodeviations angle changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression of CXCR4 on immune cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Presence of embryo sac in uterus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Variation from basal levels of biomarkers of brain, heart, kidney and endothelial injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trauma symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maximum tolerated dose (MTD) of HIPEC carboplatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pattern of visual field loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Sensitivity of rhPSMA-7.3 (18F)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of rhPSMA-7.3 (18F)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Serum Concentration (Cmax) Of Ravulizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trough Serum Concentration (Ctrough) Of Ravulizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change In Free Complement Component C5 (C5) Concentrations Over Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Average efficacy of the first ICD shock
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in the nature of pain severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the nature of fatigue severity
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Subjective patient symptom score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: EORTC Quality of Life Questionnaire - Core 30 Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Degradation rate of visual field
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Degradation rate of visual function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Electrophysiological activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Degree of analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of a Major Depressive Episode
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in lumbar spine aBMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance Binocular Visual Acuity (logMAR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Near Binocular Visual Acuity (logMAR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantitative Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under Contrast Sensitivity Function Curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Patients with KIR Favorable Donor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of patients reporting specific conditions present
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of cardiovascular-related mortality, myocardial infarction, or stroke
Endpoint domain: Mortality/survival
Primary endpoint: AV Interval Determination Using Impedance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AV Interval Determination Using Heart Sounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Optimal Electrode Configuration Determination Using Impedance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Optimal Electrode Configuration Determination Using Heart Sounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of TST/I 131 TST
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in LVEF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes from baseline in Oxygen Delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful Deployment of Tissue Apposition System (TAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Area Under Curve of 0-4 Hours Postprandial Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Adverse Events in Stage A
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Change From Baseline in Nasal Congestion Over a 6-hour Period in the EEC at Day 5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of hypoglycaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of complications related to peripheral intravenous catheter
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Postoperative neurocognitive disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Non-elective hospitalisation episodes
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change From Baseline in the Eczema Area and Severity Index (EASI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: treatment related serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement of the Gastrointestinal Quality of Life Index (GIQLI)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Heroin abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum biomarker expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Box and Blocks test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Removal of inflammatory mediators
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Target MDRO Growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: EBP Competence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Self-Efficacy and attitudes
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Participant Satisfaction with EBP Teaching
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Health status at 6 months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Ultrasound changes in muscle cross-sectional area of the transversus abdominis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Ultrasound changes in muscle cross-sectional area of the internal oblique
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Ultrasound changes in muscle cross-sectional area of the external oblique
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Ultrasound changes in muscle cross-sectional area of the rectus abdominis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Ultrasound changes in muscle cross-sectional area of the lumbar multifidus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Patient retention rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Stress Reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change from baseline blood glucose at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change from baseline insulin at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change from baseline thyroid hormone at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: change from baseline urine iodine concentration at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Anti-tumour response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Value of log10 hepatitis B virus (HBV) DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mean Nighttime Total Sleep Time
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Recurrent PE
Endpoint domain: Mortality/survival
Primary endpoint: Deep vein thrombosis (DVT)
Endpoint domain: Mortality/survival
Primary endpoint: Complete clinical clearance (CCC) per field
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in AK-FAS (AK field assessment scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Investigator global score (IGS) of each field
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in cardiac autonomic regulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADHD Rating Scale - IV (ADHD-RS-IV)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Accuracy of IRT to detect fever
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histologic regression to benign endometrium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in blood insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in gut hormones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Observed therapist behaviors
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: change of peak flow velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: change of flow volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants with stasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number of Participants with deep venous thrombosis
Endpoint domain: Adverse events/effects
Primary endpoint: Cross-sectional area of the jugular veins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in hemispatial neglect symptomatology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Fracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in actigraphically measured sleep behavior
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in sleep diary reported sleep behavior
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in the level of subjective mood
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in the level of subjective sleepiness
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in sleep knowledge
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Change in time use
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Pain Impact
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Patients With Clinical Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma concentrations of methylphenidate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area-under-the-curve (AUC) of the gametocyte concentration-time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of reinfection during the 9-week follow-up period
Endpoint domain: Adverse events/effects
Primary endpoint: Sum of omega-3 fatty acid levels in membrane phospholipids of RBC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: acceptability of intervention
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of severe graft versus host disease (GVHD) grade C or D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: No of Subjects with Major adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Decrease in ODI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maintenance of post-operative disc height
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in quality of patient recovery
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: dilatation of peripheral blood vessels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: macrophages and fibroblasts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in subjective hunger
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sensitivity of the device
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Specificity of the device
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Yale-Brown Obsessive-Compulsive Scale total score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: incidence of Severe Infections by Gram Negative Bacteria
Endpoint domain: Adverse events/effects
Primary endpoint: perioperative plasma concentrations of brain natriuretic peptide (BNP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Management of simulated patient encounter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: safety of KS24.22 administration
Endpoint domain: Adverse events/effects
Primary endpoint: Auditory Verbal Learning Test (AVLT)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Brief Visuospatial Memory Test-Revised (BVMT-R)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Digital span (DS)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Trail Making Test-A (TMT-A)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: TMT-B
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Stroop test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mean Score of Hopkins Verbal Learning Test (Total)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mean Fasting Glucose Measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Markers of Inflammation (C-reactive Protein)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sensitivity of 18F-DCFPyL PET/CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Leg Length Inequality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ilium Anterior Tilt Difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pelvic Inclination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Estimated Steady-State Maximum Plasma Concentration (Cmax,ss) of Sunitinib and Its Metabolite
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Estimated Area Under the Plasma Concentration Versus Time Curve From Time Zero to 24 Hours Post Dose AUC(0-24) of Sunitinib and Its Metabolite
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Estimated Oral Clearance (CL/F) of Sunitinib and Its Metabolite
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence, nature and severity of adverse events of special interest
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence, nature and severity of bevacizumab related serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Onset time of adverse event associated with bevacizumab
Endpoint domain: Adverse events/effects
Primary endpoint: haemoglobin levels in g/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: change in haemoglobin levels over time (in g/dL and %)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: number and proportion of patients with haematopoietic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes